39mon MSN
The 10 best movies of 2025
When it comes to movies, it’s very possible that 2025 will be remembered more for what happened off the screen than on it.
WCJB TV20 on MSN
Political points: Tracking North Central Florida politics, campaigns, and governance
WCJB TV20 provides regular updates on the latest news in politics, campaigns, and governance across North Central Florida.
Controversial content creator Bonnie had been getting up to no good on her infamous Bang Bus tour down under, but now she has ...
These stocks have rewarded shareholders generously in the last few years. The underlying businesses, on the other hand, leave much to be desired.
Hit play on the player below to hear the podcast and follow along with the transcript beneath it. This transcript was ...
YouTubeTV is planning an expansion of its subscription into tiers, allowing existing subscribers to save money on the channels they're actually watching.
One Chicago Center on MSN
Chicago Fire, Med, and PD won’t be back until 2026, but here’s how you can catch up beforehand
December is nearing the halfway point, and the One Chicago shows have officially been off the air for a month now. Chicago ...
MiBolsilloColombia on MSN
Tariff outlook for 2026 signals pressure ahead for US import flows
Import volumes are sliding as tariffs, labor uncertainty, and early stockpiling reshape supply chains entering 2026.
DPA International on MSN
Austria adopts law banning headscarves for girls under 14 in schools
Muslim girls under the age of 14 will no longer be allowed to wear headscarves in Austrian schools, according to an amendment ...
Ball Durham on MSN
Duke basketball in heated battle with SEC foe for elite 5-star guard
Duke could end up in a heated battle with SEC foe Arkansas, which is reportedly picking up steam in Smith's recruitment.
Cryptopolitan on MSN
Which Crypto to Buy Today for Long-Term? MUTM Predicted to Hit $0.50
Long-term crypto investors look beyond daily price swings. They focus on projects with strong product fundamentals, cl ...
The FDA is reviewing the safety of two drugs, Clesrovimab and Nirsevimab, which are approved for the prevention of RSV in infants and toddlers, and are 80-90% effective at reducing the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results